{{Rsnum
|rsid=7527798
|Gene=CR1L
|Chromosome=1
|position=207698945
|Orientation=plus
|GMAF=0.141
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CR1L
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 9.7 | 40.7 | 49.6
| HCB | 0.0 | 7.3 | 92.7
| JPT | 0.9 | 6.2 | 92.9
| YRI | 0.0 | 4.8 | 95.2
| ASW | 1.8 | 14.0 | 84.2
| CHB | 0.0 | 7.3 | 92.7
| CHD | 0.0 | 10.1 | 89.9
| GIH | 0.0 | 12.9 | 87.1
| LWK | 0.0 | 10.0 | 90.0
| MEX | 3.4 | 20.7 | 75.9
| MKK | 2.6 | 17.6 | 79.7
| TSI | 8.8 | 33.3 | 57.8
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=21700265
|Trait=None
|Title=Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate.
|RiskAllele=
|Pval=2E-9
|OR=0.1000
|ORtxt=[NR] unit increase
|OA=1
}}

{{PMID Auto
|PMID=22430674
|Title=Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease.
|OA=1
}}

{{PMID Auto
|PMID=23856853
|Title=Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}